Market Overview

RBC Says New Dosing for Allergan's DARPin Could Be Positive for Regeneron's Eylea

Share:
Related REGN
Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma
Credit Suisse: Regeneron Now Worth $550/Share
Amgen gets cholesterol edge (Investor's Business Daily)
Related AGN
Viking Global Liked AIG, Google, Actavis, Illumina And Cheniere Energy Last Quarter
John Paulson Continues To Bet On Health Care And TV
Time Warner Is A Buy - Cramer's Lightning Round (5/21/15) (Seeking Alpha)

RBC's Adnan Butt issued a note Wednesday morning suggesting the every-other-month dosing of Allergen's (NYSE: AGN) DARPin may solidify the longer-term market position for Regeneron's (NASDAQ: REGN) Eylea.

The analyst pointed out Allergan's Phase 2 study evaluating this same method "in a schedule almost identical to Eylea's."

RBC sees the study completed later this year, with the Phase 3 trial slated for completion by yearend 2014 or early 2105. This schedule of studies could indicate DARPin sales starting as soon as 2019.

RBC maintains an Outperform rating and $286 price target on shares of Regeneron Pharma.

Latest Ratings for REGN

DateFirmActionFromTo
May 2015CitigroupMaintainsBuy
May 2015Credit SuisseAssumesOutperform
May 2015Leerink SwannMaintainsOutperform

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Analyst Color Analyst Ratings

 

Related Articles (REGN + AGN)

Around the Web, We're Loving...